logo
  

Takata Has Enough Funds To Handle A Global Recall: Nikkei

Japanese air bag maker Takata Corp. (TKTDF.PK) said it has sufficient funds to handle a global recall, Nikkei reported citing an interview with the company's chief executive Shigehisa Takada, the grandson of Takata's founder.

Carmakers, including Honda Motor Co. and Toyota Motor Corp., have recalled over 20 million vehicles worldwide due to issues related to Takata's air bags.

Earlier this month, Takata unveiled several safety measures as its faulty airbags reportedly caused at least five deaths in the U.S. However, the auto parts supplier stopped short of a nationwide recall as demanded by the National Highway Traffic Safety Administration.

U.S. regulators are considering legal procedures if Takata does not comply with a request to expand recalls.

Takata has earmarked $774 million to deal with recalls. Takada said the firm is prioritizing the supply of replacement parts, and it has sufficient funds put aside, adding the company is not concerned of under-capitalization.

From January 2015, the Tokyo-based company will accelerate production at its Mexico plant by 30 percent to 450,000 units per month to be supplied in North America. It will also increase output capacity in China and Germany to make replacements for other markets within a year.

The stock added 4.7 percent in Tokyo trading on Thursday to 1,327.00 yen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT